Cipla Q2 Profit Falls 35% as US Sales Weaken

Summary: Cipla reported a 35% year-on-year fall in Q2 FY27 attributable profit to ₹878 crore as North America revenue dropped 19%, outweighing 12% growth in India. Revenue from operations slipped 2% to ₹7,404 crore, while EBITDA margin stood at 18.7%. The stock fell as much as 2.7% after the results, even as the Nifty Pharma index gained, highlighting investor concern over the US business.

Cipla’s September-quarter results presented a split picture: a resilient domestic franchise and improving sequential sales, but a difficult year-on-year comparison in North America that pulled down profit. The company released its unaudited Q2 FY27 numbers on October 27, 2026.

What Happened

Profit attributable to Cipla’s owners fell to ₹877.54 crore from ₹1,351.17 crore a year earlier. Revenue from operations declined 2% to ₹7,403.93 crore, while EBITDA dropped to ₹1,388 crore from ₹1,895 crore. The EBITDA margin was 18.7%, versus 25% a year earlier, though it improved by 200 basis points sequentially.

Business-wise, India revenue rose 12% to ₹3,516 crore. North America revenue fell 19% to ₹1,643 crore, while US dollar revenue was $172 million, up $10 million from the preceding quarter. Cipla’s published figures also showed South Africa private-market growth of 6.5%, ahead of its cited 5% market growth.

Why It Matters

India is now doing more of the work in Cipla’s growth mix, while the US portfolio faces a tougher comparison as sales of generic Revlimid moderate. That matters because complex launches and execution in North America can have an outsized effect on margins. Cipla’s US pipeline includes the recently approved generic Advair Diskus and a partnership for a Keytruda biosimilar.

The company’s stated net cash position of ₹9,823 crore and ₹423 crore of quarterly research and development spending provide capacity for launches and portfolio investment. Investors will still need evidence that new products can replace revenue from maturing opportunities.

Market Impact

Cipla shares fell as much as 2.7% to ₹1,319 on October 27, Reuters reported, while the Nifty Pharma index gained about 1.9%. The divergence shows a demonstrated negative share-price reaction to the results, particularly the profit decline and North America weakness.

Industry Context

Indian drugmakers are balancing dependable domestic demand with price erosion and product cycles in the United States. Cipla’s 12% India growth contrasts with its 19% North America decline, making the geographic mix especially important this quarter. For another recent example of US-market pressure on an Indian pharmaceutical company, read BusinessNews1’s Dr Reddy’s Q2 results report.

What To Watch Next

Watch the pace of Cipla’s US launches, the commercial contribution from generic Advair Diskus, and whether North America can sustain sequential improvement. In India, prescription growth and the rollout of Yurpeak, the obesity treatment licensed from Eli Lilly, are key. Margin recovery and the replacement of maturing US products will remain central to the next-quarter debate.

FAQs

What was Cipla’s Q2 FY27 profit?

Cipla reported profit attributable to owners of ₹877.54 crore, rounded to ₹878 crore, for the quarter ended September 30, 2026. That compared with ₹1,351.17 crore a year earlier. Total revenue from operations was ₹7,403.93 crore, about 2% lower year on year.

Why did Cipla’s profit fall?

The main pressure came from North America, where revenue fell 19% to ₹1,643 crore as sales of key products moderated. EBITDA also fell to ₹1,388 crore from ₹1,895 crore. India partly offset the weakness, but its 12% growth was not enough to prevent the consolidated decline.

How did India and North America perform?

Cipla’s One-India business posted quarterly sales of ₹3,516 crore, up 12% year on year. North America generated ₹1,643 crore, down 19%, although dollar revenue of $172 million was $10 million above the immediately preceding quarter. The contrast shows where near-term earnings pressure is concentrated.

How did Cipla shares react?

Cipla shares fell as much as 2.7% to ₹1,319 on October 27 after the results, according to Reuters, while the Nifty Pharma index was up about 1.9%. That relative underperformance indicates a demonstrated negative market reaction to the earnings and the weaker North America comparison.